SCHEMBL9903182

SCHEMBL9903182

Cc1ccc(C)c(OC2CCN(C(=O)O)CC2)c1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.46
TSHR P16473 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HTT P42858 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
RAB9A P51151 1/20 0.42
POLB P06746 1/20 0.41
HRH1 P35367 2/20 0.41
CCR3 P51677 2/20 0.41
CYP2C9 P11712 1/20 0.40
CSF1R P07333 1/20 0.40
PDGFRB P09619 1/20 0.40
KIT P10721 1/20 0.40
DDR1 Q08345 1/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4682397 0.86 EPHX2 (0.46) EPHX2HRH1CCR3CSF1RPDGFRB
SCHEMBL9903138 0.86 CCR3 (0.46) EPHX2KDM4ERAB9AHRH1CCR3
SCHEMBL9903020 0.84 BCHE (0.50) EPHX2ALDH1A1HTTL3MBTL1
SCHEMBL9903544 0.82 EPHX2 (0.62) EPHX2KDM4ERAB9AHRH1KMT2A
SCHEMBL5536788 0.80 HTR2C (0.46) TSHRKDM4EALDH1A1HTTL3MBTL1
SCHEMBL2636897 0.79 EPHX2 (0.60) EPHX2HRH1CCR3KMT2AMEN1
SCHEMBL5536784 0.79 SYK (0.41) TSHRKDM4EALDH1A1HTTL3MBTL1
SCHEMBL25356273 0.78 HRH3 (0.45) EPHX2HRH1CCR3KMT2A
SCHEMBL19384583 0.77 EPHX2 (0.51) EPHX2KDM4EALDH1A1HRH1CYP2C9
SCHEMBL12794525 0.76 ADRB2 (0.48) TSHRKDM4EALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946225-B2 Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors PIERRE FABRE MEDICAMENT (FR) 2015-02-03 US claimed
US-20120178678-A1 DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS PIERRE FABRE MEDICAMENT (FR) 2012-07-12 US claimed
EP-2462121-A1 DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS Pierre Fabre Médicament (FR) 2012-06-13 EP claimed
EP-2462121-B1 DERIVATIVES OF 2H PYRIDAZIN-3-ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS PF MEDICAMENT (FR) 2015-02-18 EP disclosed
US-8946225-B2 Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors PIERRE FABRE MEDICAMENT (FR) 2015-02-03 US disclosed
US-20120178678-A1 DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS PIERRE FABRE MEDICAMENT (FR) 2012-07-12 US disclosed
EP-2462121-A1 DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS Pierre Fabre Médicament (FR) 2012-06-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178678-A1 DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS SCD, SCD5, CYP2S1 EPHX2 1211/4885TSHR 1424/4885KDM4E 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.